UA138969U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of endothelin, folic acid, cartilaginous oligomeric matrix protein (COMP), homocysteine. With a homozygous carrier of 677-TT and levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP), homocysteine, and in the case of homozygous carrier 677-HT are determined in the patient's blood serum endothelin 210 ng/ml, folic acid "6 ng/ml, COMP" 595 ng/ml, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, and the MTNEK S677T gene polymorphism is determined. The content of endothelin, folic acid, COMP, and homocysteine is determined by the immunoenzymatic method. With a homozygous carrier of 67 7-TT, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, COMP "595 ng/ml, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient G., 68 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The MTNEK C677T gene polymorphism was determined in blood serum. The content of endothelin, folic acid, COMP, and homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-117 was established.

Levels of endothelin - 20 ng/ml, folic acid - 3.6 ng/ml, COMP - 785 ng/ml, homocysteine - 42 μmol/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, X-ray photography, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV Сб677Т), the content of endothelin, folic acid, cartilage oligomeric matrix protein (COMP), homocysteine is additionally determined in the patient's blood serum, and in the case of homozygous carrier 677-171 and levels of endothelin 210 ng/ml, folic acid "b ng/ml, COMP" 595 ng/ml, homocysteine 220 μmol/l predict the development of osteoarthritis.